Organon Pharma Indonesia Tbk. vs Trias Sentosa Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Trias Sentosa Tbk. trades at Rp462 (market cap 1.3T, 65.4K 24h volume). The key difference: Trias Sentosa Tbk. is far larger — about 12.5× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | TRST | |
|---|---|---|
Market Cap | 104.4B | 1.3T |
Volume | — | 65.4K |
Lot | — | 654 |
Turnover | — | 30.18M |
Average Price | — | 461.54 |
Value | — | 30.18M |
Indicative Equilibrium Price | — | 462 |
Indicative Equilibrium Volume | — | 435 |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Trias Sentosa Tbk was established on November 23, 1979 and started commercial operation in 1984 with total capacity of 4.500 tons BOPP (biaxially oriented polypropylene) film per annum. In 1989, the Company completed expansion of its second line BOPP film with capacity of 7.500 tons per annum. In 1993, the Company completed its expansion of third line BOPP film with capacity of 12.000 tons per annum, and in 1995, Polyester film project with total capacity of 12.000 tons were completed. In 1996, the Company completed its expansion of fourth line BOPP film with total capacity of 16.000 tons. Currently, the Company is the largest BOPP Film and Polyester Film producer in Indonesia.
Read more on TRST →